Objective: To observe the effects of montelukast combined with vitamin D preparations on pulmonary function

oxidation-antioxidant imbalance and quality of life in children with bronchial asthma. Methods: A total of 95 children with bronchial asthma were divided into the observation group (n=48 cases) and the control group (n=47 cases) according to the random number table. The control group was treated with montelukast chewable tablets on the basis of conventional treatment

and the observation group received vitamin D preparations on the basis of the control group. Both groups were treated for 8 weeks. Serum level of vitamin D

Childhood Asthma Control Test (C-ACT) score

lung function and oxidative stress of two groups were recorded

and improvement of quality of life were compared. Results: After treatment

the serum level of 25-(OH)D in the observation group was (30.87±6.49) ng/mL

higher than that before treatment (23.93±7.34) ng/mL (P<0.05)

there was no statistical significance in the control group before and after treatment (P>0.05). After treatment

the serum level of 25-(OH)D in the observation group was higher than that in the control group (24.20±7.91) ng/mL (P<0.05). After treatment

the C-ACT grading and average score of two groups were higher than those before treatment (P<0.05)

and the C-ACT grading and average score of the observation group after treatment were higher than those of the control group (P<0.05). After treatment

FEV1

FEV1/FVC

PEF and PEFR in both groups were all higher than those before treatment (P<0.05)

the above indicators in the observation group after treatment were higher than those in the control group (P<0.05). After treatment

the serum levels of SOD and GSH-Px in both groups were significantly higher than those before treatment

and the serum levels of MAD were significantly lower than those before treatment (P<0.05). After treatment

SOD and GSH-Px of the observation group were higher than those of the control group

and MAD was lower than that of the control group (P<0.05). The four dimension scores and total scores in Chinese version of pediatric quality of life inventory TM (PedsQL) in two groups after treatment were significantly higher than those before treatment (P<0.05)

and the above scores in the observation group were higher than those in the control group (P<0.05). There was no statistically significant difference in the incidence of adverse drug reactions between the observation group and the control group (8.33% vs 6.38%

P>0.05). Conclusion: Montelukast combined with vitamin D preparations can significantly improve the level of vitamin D in children with bronchial asthma

improve the lung function

promote the oxidation-antioxidant balance

inhibit oxidative stress

and contribute to the improvement of asthma control and quality of life.